Nephrogenic systemic fibrosis: Recommendations for gadolinium-based contrast use in patients with kidney disease

Seminars in Dialysis

Volumn 21, Issue 2, 2008, Pages 171-173

  Perazella, Mark A ^a   Reilly, Robert F ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM;

ARTICLE; DRUG CONTRAINDICATION; FIBROSIS; HUMAN; KIDNEY DISEASE; PRACTICE GUIDELINE; RISK FACTOR;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; HUMANS; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 40849085209     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00402.x     Document Type: Article

References (18)

1. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE : Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356 : 1000 1001, 2000
2. Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE : Nephrogenic fibrosing dermopathy. Am J Dermatopathol 23 : 383 393, 2001
3. Cowper SE, Boyer PJ : Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 8 : 151 157, 2006
4. Cowper SE : Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46 : 763 765, 2005
5. Grobner T : Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21 : 1104 1108, 2006
6. Marckmann P, Skov L, Rossen K, Dupont A, Damholt M, Heaf JG, Thomsen HS : Nephrogenic systemic fibrosis: suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 : 2359 2362, 2006
7. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA : Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 188 : 586 592, 2007
8. Khurana A, Runge VM, Narayanan M, Greene JF, Nickel AE : Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42 : 139 145, 2007
9. Deo A, Fogel M, Cowper SE : Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2 : 264 267, 2007
10. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. Morb Mortal Wkly Rep 56 : 137 141, 2007
11. Sadowski EA, Bennett LK, Chan MR, et al. : Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243 : 148 157, 2007
12. Marckmann P, Skov L, Rossen K, Heaf J, Thomsen HS : Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 : 3174 3178, 2007
13. Stenver DI : Investigation of the Safety of MRI Contrast Medium Omniscan. Danish Medicines Agency. Published May 29, 2006. Available at: http://www.dkma.dk/1024/visUKLSArtikel.asp?artikelID=8931. Accessed December 7, 2006
14. High WA, Ayers RA, Chandler J, Zito G, Cowper SE : Gadolinium is detectable within the tissues of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 : 21 26, 2007
15. Boyd AS, Zic JA, Abraham JL : Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56 : 27 30, 2007
16. High WA, Eng M, Ayers RA, Cowper SE, : Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56 : 1 2, 2007
17. Food and Drug Administration (2006) Public Health Advisory: Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging (MRI). Available at: http://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222. htm
18. Joffe P, Thomsen HS, Meusel M : Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5 : 491 502, 1998